Biosimilars and Originator Biologics 2023 | C5 Group Inc. | TBA, Munich, Germany

Benefit from in-depth discussions which will allow you to:

• Comprehend how global affairs are transforming the development and commercialization of biologics and biosimilars
• Analyse the global legal and business ramifications of the EMA and FDA biosimilar regulatory pathways
• Understand the significance of regulatory exclusivities in biosimilar development from the perspectives of both originators and biosimilars
• Evaluate the impact of the current SPC landscape and the implementation of the UPC
• Traverse the complexities of U.S. market entry: naming, labeling, and marketing concerns
• Implement winning strategies to prevent compliance breaches of EU competition law
• Learn how AI and data mining accelerate drug discovery and development

2023 Partners

• Dechert
• Patsnap
• Sterne Kessler